Crisis at Organon: Leadership Ousted Amid Sales Scandal

The pharmaceutical firm Organon & Co. is confronting its most severe corporate challenge to date following the discovery of manipulated sales figures. This controversy has not only resulted in the departure of its chief executive but has also inflicted significant damage on investor confidence. The company now faces critical questions about its future viability and the possibility of a strategic recovery.

The financial markets responded swiftly and harshly to the news. Organon’s stock plummeted to a fresh 52-week low, shedding as much as 22% in a single trading session after the announcement. The sell-off was compounded by a decisive downgrade from investment bank Piper Sandler, which shifted its rating from “Overweight” Read more...